Financials

  • Market Capitalization 6.3659 B
  • Employee 275
  • Founded 1989
  • CEO N/A
  • Website www.amarincorp.com
  • Headquarter United Kingdom
  • FIGI BBG000BPYG99
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-155.06
Price to sales ratio
27.11

Amarin Corporation plc - American Depositary Shares, each repre

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid. In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza.

뉴스